54 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
for any product candidates we may develop; the pricing and reimbursement of our product candidates, if approved, including the possibility for reduced … , are likely to be their efficacy, safety, convenience, price, level of generic competition, and availability of reimbursement. Manufacturing We do not own
8-K
EX-10.1
pjl93avnzt0s
30 May 23
Entry into a Material Definitive Agreement
7:30am
ARS
swyncpeinqb na
28 Apr 23
Annual report to shareholders
7:03am
8-K
EX-99.1
20eef4 cv47d
4 Aug 22
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8:15am
8-K
EX-10.1
yd4enozxw 55ukgbn
30 Nov 21
Entry into a Material Definitive Agreement
4:18pm
S-3ASR
EX-4.4
17zqfy2md
10 Nov 21
Automatic shelf registration
5:19pm
S-3ASR
EX-1.2
apengb u1zx
10 Nov 21
Automatic shelf registration
5:19pm